BackgroundDespite its limitations, in part due to decreased speci city in advanced disease, serum lactate dehydrogenase (LDH) is one of few serum factors used in cancer staging.
ObjectivesThis study quanti es the predictive capabilities of LDH in stage IV melanoma of the skin and explores the validity of suggested demographic discrepancies which may exist in its use.
MethodsThe 1975-2017 Surveillance Epidemiology and End Results (SEER) database was queried for stage IV cutaneous melanoma cases. Demographic characteristics were compared between LDH groups using chi-square and t-tests. Subsequent Cox multivariable regression was performed to assess survival differences.
Results334 cases of stage IV cutaneous melanoma (average age: 63.0 years) with measured serum LDH levels were identi ed. Of these patients, 150 (44.9%) had normal LDH, 112 (33.5%) had LDH < 1.5x upper limit of normal (ULN), 57 (17.1%) had LDH 1.5-10x ULN, and 15 (4.5%) had LDH > 10x ULN. Lower incomes were associated with higher LDH; individuals with incomes <$50,000 had the greatest proportion of LDH 10x ULN (19.2%; p = 0.0031). LDH > 10x ULN also had the lowest proportion of White patients (p = 0.04). On Cox multivariable survival analysis, increasing LDH levels showed increased risk of death (LDH < 1.5x ULN: HR = 2.05, p = 0.01; LDH 1.5-10x ULN: HR = 1.46, p < 0.001; LDH > 10x ULN: HR = 5.91, p < 0.001).
ConclusionThis study rea rms the utility of LDH as a signi cant predictor of mortality with incremental severity, suggesting possible use for mortality projections. We note that Black patients and those with lower incomes may be more likely to have an elevated LDH. Older age groups and presence of ulceration among patients with stage IV melanoma were also associated with a greater risk of mortality.